Einloggen

Thematische Bibliographien / Inflammatory bowel diseas / Zeitschriftenartikel

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Inflammatory bowel diseas.

Zeitschriftenartikel zum Thema „Inflammatory bowel diseas“

Autor: Grafiati

Veröffentlicht am 1. Februar 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Inflammatory bowel diseas" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

KASKI, M. CARPANI, und H. J. F. HODGSON. „Rolling review: inflammatory bowel diseas“. Alimentary Pharmacology & Therapeutics 7, Nr. 5 (31.03.2007): 567–79. http://dx.doi.org/10.1111/j.1365-2036.1993.tb00134.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

O’Sullivan, Maria, und Colm O’Morain. „Nutritional therapy in inflammatory bowel diseas“. Current Treatment Options in Gastroenterology 7, Nr. 3 (Juni 2004): 191–98. http://dx.doi.org/10.1007/s11938-004-0040-2.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Mancho, Carolina, Ángel Sainz, Mercedes García-Sancho, Alejandra Villaescusa, Miguel A. Tesouro und Fernando Rodríguez-Franco. „Detection of Perinuclear Antineutrophil Cytoplasmic Antibodies and Antinuclear Antibodies in the Diagnosis of Canine Inflammatory Bowel Diseas“. Journal of Veterinary Diagnostic Investigation 22, Nr. 4 (Juli 2010): 553–58. http://dx.doi.org/10.1177/104063871002200409.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Theocharidou, Eleni, Melachrini Mavroudi, Konstantinos Soufleris, Alexandros Mpoumponaris, Andreas Nakos, Theodora Griva, Nikolaos Grammatikos, Eleni Mavroudi, Geleris Paraschos und Nicolaos Evgenidis. „T1333 Increased Pulse Wave Velocity in Patients With Inflammatory Bowel Diseas. Preliminary Results of an Ongoing Study“. Gastroenterology 138, Nr. 5 (Mai 2010): S—539. http://dx.doi.org/10.1016/s0016-5085(10)62486-9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Alexander, Richard J., Asit Panja, Evonne Kaplan-Liss, Lloyd Mayer und Robert F. Raicht. „Expression of growth factor receptor-encoded mRNA by colonic epithelial cells is altered in inflammatory bowel diseas“. Digestive Diseases and Sciences 40, Nr. 3 (März 1995): 485–94. http://dx.doi.org/10.1007/bf02064355.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Eindor, A., L. Meleady und K. Jacobson. „P147 Progression to biologic treatment in very early onset inflammatory bowel disease patients- a long term follow up retrospective study“. Journal of Crohn's and Colitis 15, Supplement_1 (01.05.2021): S229—S230. http://dx.doi.org/10.1093/ecco-jcc/jjab076.274.

Der volle Inhalt der Quelle

Annotation:

Abstract Background Very early onset inflammatory bowel disease (VEOIBD) prevalence has been increasing over the last decades. These young patients have been known to have special disease characteristics and disease location. Although it is known that only a low percentage of these patients require biologic treatment after diagnosis, there is only scarce evidence about their long- term outcome and biologic requirements. We aimed to assess the long term outcome of VEOIBD patients and the time of progression to biologic treatment. Methods We retrospectively reviewed IBD patients diagnosed under 6 years of age, between January 2005 and December 2019, from the British Columbia (BC) Pediatric IBD database. Demographic data, disease characteristics and symptoms at diagnosis were documented. The disease location and severity were documented according to the Paris classification. Data collected retrospectively until the last appointment recorded in the electronic medical records included whether the patient received biologic treatment at the time of follow up, the time to intiation of the treatment, the type of biologic treatment and response. Kaplan meier curves were used to asses the number of years to progression to biologic treatment and the parameters influencing it. Results 89 patients under the age of 6 were diagnosed with IBD during the study period. 3 patients failed to meet inclusion criteria and were excluded. Median age at diagnosis was 3.8 (IQR 2.6–5.1). 45.3% of patients had Crohn’s disease (CD) and 62.8% were males. Median time of follow up was 6.39 (IQR 3.71–10.55). 68.1% of the ulcerative colitis (UC) patients had pancolitis and 48.7% of CD patients had ileocolonic disease. 39.5% of patients were started on biologic treatment and 7.1% underwent surgery. Kaplan Meier curves demonstrated that patients diagnosed in the years 2012 -2019 had shorter duration of progression to biologics than those diagnosed 2005–2011 (p=0.0047). In patients with CD those with perianal or stricturing disease progressed faster to biologic treatment (p=0.024,p=0.038, respectively) and in UC patients those with high severity of disease (p=0.017). 63.6% of patients were reported to be on clinical remission on the biologic treatment. Conclusion Although VEOIBD patients have more extensive diseas, they require less biologic treatment than previously reported in older patients. Factors influencing shorter duration of progression to biologics were the severity of disease and behaviour and not disease location. Patients diagnosed more recently had shorter duration to biologic treatment which might reflect physicians perception on using biologic treatment in these young patients rather than disease severity.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Falcón-Guerrero, Britto Ebert. „Coincidencia entre la periodontitis y la enfermedad inflamatoria del intestino“. Kiru 20, Nr. 1 (31.03.2023): 28–33. http://dx.doi.org/10.24265/kiru.2023.v20n1.03.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

HUSNÍK, R., J. KLIMEŠ, K. TOMANOVÁ, J. SMOLA, R. HALOUZKA, F. TICHÝ und J. BRÁZDIL. „Lawsonia intracellularis in a dog with inflammatory bowel disease“. Veterinární Medicína 48, No. 5 (30.03.2012): 141–45. http://dx.doi.org/10.17221/5761-vetmed.

Der volle Inhalt der Quelle

Annotation:

A two-year-old male German short-haired pointer was presented with a 1.5-year history of intermittent small-bowel diarrhoea. Inflammatory bowel disease (chronic lymphocytic-plasmacytic gastritis, enteritis and colitis) was diagnosed on the basis of histological examination of biopsies obtained on repeated endoscopy and by exclusion of other possible causes. Warthin-Starry silver staining of stomach mucosa revealed the presence of gastric spiral organisms. The evidence of L. intracellularis was provided by a positive nested polymerase chain reaction in one biopsy of duodenal mucosa and in one rectal smear. In 5 blood sera collected over a period of 8 months the IgG antibodies to L. intracellularis were found by an indirect fluorescent antibody test. Treatment with oral prednisone led only to a temporary improvement.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Fernandes, Isabel, und Lúcia Gil. „Qualidade de vida da pessoa com doença inflamatória intestinal“. Revista de Enfermagem Referência IV Série, Nr. 23 (23.12.2019): 89–98. http://dx.doi.org/10.12707/riv19048.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Kumar Kasula Suresh, Bharath. „Emerging Therapies for Inflammatory Bowel Disease: A Systematic Overview“. International Journal of Science and Research (IJSR) 13, Nr. 3 (05.03.2024): 1449–51. http://dx.doi.org/10.21275/mr24322201434.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Kumar, Puneet, Sunita Devi, Pramod Kumar, Nisha Devi und Shivali Singla. „A Review on Inflammatory Bowel Disease: Diagnosis and Treatment“. International Journal of Science and Research (IJSR) 11, Nr. 4 (05.04.2022): 412–14. http://dx.doi.org/10.21275/sr22406110623.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

S, Hajare. „A Demographic Profile of Inflammatory Bowel Disease in Uttar Karnataka“. Gastroenterology & Hepatology International Journal 4, Nr. 2 (22.07.2019): 1–7. http://dx.doi.org/10.23880/ghij-16000165.

Der volle Inhalt der Quelle

Annotation:

Inflammatory bowel disease (IBD) results from production of dysregulated gut mucosal immune response to luminal antigens. Scientific literature pertaining to Southern part of Indian is limited, especially with focus on demographic and clinical phenotypes of IBD. Hence, the present study is aimed at evaluating these factors in a geographic area of Uttar Karnataka in two types of IBD- Ulcerative colitis (UC) and Crohn’s disease (CD). Methodology: A retrospective study was done with 91 patients with IBD from 2009 to 2019. Patients were routinely started on treatment with local and systemic 5-aminosalicylic acid derivatives. Different line of therapies was administered to both UC and Crohn’s disease with different drugs or combination of drugs. Results: Of the 91 patients, 85 were having UC and 6 with CD. The mean age of patients with UC and CD was 41.8 years and 52.2 years; male predominance was observed in UC group of patients in contrast to CD group. UC patients were found with Extraintestinal manifestation i.e. Erythema nodosum (0.01%), Type 1 peripheral arthritis (0.01%), Type 2 peripheral arthritis (0.01%). A total of 6 UC patients required surgery for various causes, with the majority being males, including 2 of them who developed cancer. Conclusion: There was a predominance of patients with UC, especially in men. The age, origin and level of education may interfere with early diagnosis. This geographical region survey provides an opportunity for understanding possible etiopathogenetic factors associated with the disease and pattern of treatment.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Bustelo, Dolores, und Tatiana Fazecas. „A importância da ultrassonografia com Doppler na doença inflamatória intestinal em pediatria“. Radiologia Brasileira 56, Nr. 5 (September 2023): IX—X. http://dx.doi.org/10.1590/0100-3984.2023.56.5e3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

Dudanova, Olga Petrovna, Nadezhda Alekseevna Larina, Lidija Valerievna Prokapovich und Anastasia Andreevna Larina. „Steatohepatitis in patients with inflammatory bowel diseases in Karelia“. Journal of Biomedical Technologies, Nr. 1 (Juni 2014): 10–17. http://dx.doi.org/10.15393/j6.art.2014.2981.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Garg, Praveen Kumar, Taruna Choudhary und Bharat Gomtiwall. „To Study of Spectrum of Inflammatory Bowel Disease in Western Rajasthan“. Asian Journal of Medical Research 8, Nr. 2 (Juni 2019): ME15—ME17. http://dx.doi.org/10.21276/ajmr.2019.8.2.me6.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Kastуukevich, L. I., O. N. Romanova, N. D. Kolomiets, K. Y. Marakhovsky, O. V. Krasko, O. N. Nazarenko und O. L. Savich. „СРАВНИТЕЛЬНАЯ ХАРАКТЕРИСТИКА РАЗНЫХ ТИПОВ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ КИШЕЧНИКА У ДЕТЕЙ“. Hepatology and Gastroenterology 7, Nr. 2 (Dezember 2023): 127–34. http://dx.doi.org/10.25298/2616-5546-2023-7-2-127-134.

Der volle Inhalt der Quelle

Annotation:

Background. Inflammatory bowel disease (IBD) is a group of idiopathic, chronic, relapsing inflammatory conditions of the gastrointestinal tract including ulcerative colitis (UC), Crohn's disease (CD), and unspecified colitis (UnC). Objective. To provide a comparative characteristic of clinical and laboratory features of various IBD types in children according to the morphology, and to identify clinical and laboratory markers of unspecified colitis in children. Material and methods. 118 pediatric patients diagnosed with chronic inflammatory bowel disease were observed. Statistical processing of clinical and laboratory data was carried out using the statistical package R, version 4.1. Results. A comprehensive examination revealed 36 patients with Crohn's disease (CD), 54 those with ulcerative colitis (UC), and 28 with UnC. It was found out that in patients diagnosed with unspecified colitis, clinical manifestations were statistically more often observed at an earlier age (28,5 months [8; 50]) in contrast to children with UC (31 months [14; 122]) and CD patients (96 months [34,5;132]) (p=0,004). All patients with IBD had significant changes in stool frequency (from 3 to 9 or more times per day), 45 (83.3%) patients with UC having blood in stool (p <0.001). Pain syndrome was less common in patients diagnosed with UnC – 22 (78,6%) (p=0,048). The two clinical and laboratory symptoms were significantly more often observed in the group of patients with UC: protein-energy malnutrition (PEM) – 24 (44,4%)(p=0.008) and anemia – 39 (72,2%) (p<0.001). Patients diagnosed with UnC had a lower platelet count (292±68) (p=0.005). CD patients had a lower mean relative lymphocyte count (30,8%) (p=0.005). The level of C-reactive protein (CRP) was significantly more often elevated in patients with UC – 30 (55,6%) (p=0,005). Conclusions. Though standard methods used for examining patients with IBD allow us to establish the diagnoses of UC and CD, such examination is not sufficient for children with UnC. It is necessary to include new molecular genetic criteria in the examination protocol for patients with IBD, which will make it possible to offer appropriate treatment at an early stage of the disease.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

K Tyagi, C., Anju Balkrishna Bhandole und Harish N Kakrani. „Evaluation of Herbal Plants Used in Treatment of Inflammatory Bowel Disease“. International Journal of Science and Research (IJSR) 11, Nr. 12 (05.12.2022): 950–57. http://dx.doi.org/10.21275/sr221212152611.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

Banakar, Ranjeeta S., und Rangaswamy R. „Spectrum of Histopathology of Inflammatory Bowel Disease in A Teaching Hospital, Bangalore“. Indian Journal of Pathology: Research and Practice 7, Nr. 2 (2018): 207–11. http://dx.doi.org/10.21088/ijprp.2278.148x.7218.13.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Mounika, Gai, Vuppunuthala Ramkamladhar, Ch Praneeth Kumar und K. Ravinder Reddy. „Unveiling Strongyloidiasis: A Mimicker of Inflammatory Bowel Disease with Unique Clinical Presentation“. International Journal of Science and Research (IJSR) 12, Nr. 9 (05.09.2023): 646–47. http://dx.doi.org/10.21275/sr23905105335.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Beal, Eliza W., Rosara Bass und Alan E. Harzman. „Two Patients with FulminantClostridium difficileEnteritis Who Had Not Undergone Total Colectomy: A Case Series and Review of the Literature“. Case Reports in Surgery 2015 (2015): 1–5. http://dx.doi.org/10.1155/2015/957257.

Der volle Inhalt der Quelle

Annotation:

Introduction.Clostridium difficileis the most common cause of healthcare associated infectious diarrhea, and its most common clinical manifestation is pseudomembranous colitis. Small bowel enteritis is reported infrequently in the literature and typically occurs only in patients who have undergone ileal pouch anastomosis due to inflammatory bowel disease or total abdominal colectomy for other reasons.Presentation of Cases. We report here two cases in which patients developed small bowelC. difficileenteritis in the absence of these underlying conditions.Discussion. Neither patient had underlying inflammatory bowel disease and both had a significant amount of colon remaining.Conclusion. These two cases demonstrate that small bowelC. difficileenteritis should be included in the differential diagnosis of patients on antibiotic therapy who demonstrate signs and symptoms of worsening abdominal disease during their postoperative course, even if they lack the major predisposing factors of inflammatory bowel disease or history of total colectomy.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Ahmed Majeed, Hiba. „Detection of Cytomegalovirus in Patients with Inflammatory Bowel Diseases in Iraq“. Journal of Communicable Diseases 55, Nr. 03 (07.12.2023): 67–74. http://dx.doi.org/10.24321/0019.5138.202341.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Patel, Parth, Richa Sharma und Yatish x. „Association of Self Medication with Analgesics and Smoking among Inflammatory Bowel Disease Patients“. International Journal of Science and Research (IJSR) 11, Nr. 9 (05.09.2022): 860–61. http://dx.doi.org/10.21275/mr22916223327.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Sewell, Justin L., und Uma Mahadevan. „Of Blemishes and Bowels: Isotretinoin and Inflammatory Bowel Disease“. Gastroenterology 138, Nr. 1 (Januar 2010): 392–94. http://dx.doi.org/10.1053/j.gastro.2009.11.029.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Hyams, J. S. „Inflammatory Bowel Disease“. Pediatrics in Review 26, Nr. 9 (01.09.2005): 314–20. http://dx.doi.org/10.1542/pir.26-9-314.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Glick, S. R., und R. S. Carvalho. „Inflammatory Bowel Disease“. Pediatrics in Review 32, Nr. 1 (31.12.2010): 14–25. http://dx.doi.org/10.1542/pir.32-1-14.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Shapiro, J. M., S. Subedi und N. S. LeLeiko. „Inflammatory Bowel Disease“. Pediatrics in Review 37, Nr. 8 (01.08.2016): 337–47. http://dx.doi.org/10.1542/pir.2015-0110.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Hyams, J. S. „Inflammatory Bowel Disease“. Pediatrics in Review 21, Nr. 9 (01.09.2000): 291–95. http://dx.doi.org/10.1542/pir.21-9-291.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Moses, Peter L., Brad R. Moore, Nicholas Ferrentino, Steven P. Bensen und James A. Vecchio. „Inflammatory bowel disease“. Postgraduate Medicine 103, Nr. 5 (Mai 1998): 77–102. http://dx.doi.org/10.3810/pgm.1998.05.483.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

Glick, Sarah R., und Ryan S. Carvalho. „Inflammatory Bowel Disease“. Pediatrics In Review 32, Nr. 1 (01.01.2011): 14–25. http://dx.doi.org/10.1542/pir.32.1.14.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Hyams, Jeffrey S. „Inflammatory Bowel Disease“. Pediatrics In Review 21, Nr. 9 (01.09.2000): 291–95. http://dx.doi.org/10.1542/pir.21.9.291.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Hyams, Jeffrey S. „Inflammatory Bowel Disease“. Pediatrics In Review 26, Nr. 9 (01.09.2005): 314–20. http://dx.doi.org/10.1542/pir.26.9.314.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

Moll, J. M. H. „Inflammatory Bowel Disease“. Clinics in Rheumatic Diseases 11, Nr. 1 (April 1985): 87–111. http://dx.doi.org/10.1016/s0307-742x(21)00590-7.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

MAYBERRY, J. F. „Inflammatory Bowel Disease“. Gut 49, Nr. 2 (01.08.2001): 314.3–314. http://dx.doi.org/10.1136/gut.49.2.314-b.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

Vatn, Morten H., und Arne K. Sandvik. „Inflammatory bowel disease“. Scandinavian Journal of Gastroenterology 50, Nr. 6 (08.04.2015): 748–62. http://dx.doi.org/10.3109/00365521.2015.1033000.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

Podolsky, Daniel K. „Inflammatory Bowel Disease“. New England Journal of Medicine 347, Nr. 6 (08.08.2002): 417–29. http://dx.doi.org/10.1056/nejmra020831.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Abraham, Clara, und Judy H. Cho. „Inflammatory Bowel Disease“. New England Journal of Medicine 361, Nr. 21 (19.11.2009): 2066–78. http://dx.doi.org/10.1056/nejmra0804647.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Schuman, Bernard M. „Inflammatory bowel disease“. Postgraduate Medicine 83, Nr. 4 (März 1988): 291–94. http://dx.doi.org/10.1080/00325481.1988.11700202.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Floch, Martin H. „Inflammatory Bowel Disease“. Journal of Clinical Gastroenterology 45, Nr. 9 (Oktober 2011): 839. http://dx.doi.org/10.1097/mcg.0b013e31822be119.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Hanauer, Stephen B., und Daan W. Hommes. „Inflammatory bowel disease“. Expert Review of Clinical Immunology 6, Nr. 4 (Juli 2010): 499–500. http://dx.doi.org/10.1586/eci.10.52.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

McClenathan, Daniel T. „Inflammatory Bowel Disease“. Journal of Pediatric Gastroenterology and Nutrition 10, Nr. 2 (Februar 1990): 277. http://dx.doi.org/10.1097/00005176-199002000-00032.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Schölmerich, J. „Inflammatory Bowel Disease“. Endoscopy 28, Nr. 01 (Januar 1996): 77–82. http://dx.doi.org/10.1055/s-2007-1005421.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

Ottenjann, R. „Inflammatory Bowel Disease“. Endoscopy 26, Nr. 01 (Januar 1994): 64–69. http://dx.doi.org/10.1055/s-2007-1005812.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Zakaria, Alan A., und Sami F. Rifat. „Inflammatory Bowel Disease“. Current Sports Medicine Reports 7, Nr. 2 (März 2008): 104–7. http://dx.doi.org/10.1097/01.csmr.0000313398.94816.47.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

Ambrose, N. S. „Inflammatory bowel disease“. Current Opinion in Gastroenterology 2, Nr. 3 (Mai 1986): 377–78. http://dx.doi.org/10.1097/00001574-198605000-00010.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Rhodes, J. M. „Inflammatory bowel disease“. Current Opinion in Gastroenterology 2, Nr. 3 (Mai 1986): 405–9. http://dx.doi.org/10.1097/00001574-198605000-00014.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

&NA;. „Inflammatory bowel disease“. Current Opinion in Gastroenterology 2, Nr. 3 (Mai 1986): 449–56. http://dx.doi.org/10.1097/00001574-198605000-00018.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

Ambrose, N. S. „Inflammatory bowel disease“. Current Opinion in Gastroenterology 3, Nr. 3 (Mai 1987): 423. http://dx.doi.org/10.1097/00001574-198705000-00009.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

Rhodes, J. M. „Inflammatory bowel disease“. Current Opinion in Gastroenterology 3, Nr. 3 (Mai 1987): 438–43. http://dx.doi.org/10.1097/00001574-198705000-00012.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

Ambrose, N. S. „Inflammatory bowel disease“. Current Opinion in Gastroenterology 3, Nr. 3 (Mai 1987): 460–64. http://dx.doi.org/10.1097/00001574-198705000-00015.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

&NA;. „Inflammatory bowel disease“. Current Opinion in Gastroenterology 3, Nr. 3 (Mai 1987): 523–32. http://dx.doi.org/10.1097/00001574-198705000-00017.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!